Skip to main content
. Author manuscript; available in PMC: 2014 Sep 27.
Published in final edited form as: Circ Res. 2013 Aug 1;113(8):10.1161/CIRCRESAHA.113.301934. doi: 10.1161/CIRCRESAHA.113.301934

Figure 4. Renal impairment and IL-17A enhance antigen presenting cell marker expression and decrease oxLDL uptake in myeloid cell differentiation.

Figure 4

(A) oxLDL uptake by human PBMC derived macrophages differentiated in the presence of serum from patients with stable chronic kidney disease (GFR above 60 ml/min=CKDI,II, n=5, GFR 30-60ml/min=CKDIII, n=11 and healthy controls (HC), n=9, 3 independent experiments, Bonferroni after One-way-ANOVA) (B) HLAII surface expression on human PBMC derived macrophages assessed by flow cytometry (CKDI,II, n=11, CKDIII, n=19, healthy controls, n=8, 6 independent experiments, Bonferroni after One-way-ANOVA). (C,D) HLAII expression on PBMC derived macrophages cultured with and without recombinant IL-17A (C,n=5, linear trend after One-way-ANOVA) and dendritic cells (D, promoted by culture with GM-CSF and IL-4, n=4, linear trend after One-way-ANOVA). (E,F) Murine macrophages were generated by culture of adherent bone marrow cells. The effect of recombinant mouse IL-17A on CD11c expression was investigated in both wt (E, 4 independent experiments) and Il17a−/− compared to Il17ra−/− mice (F, t-test after One-way-ANOVA, 3 independent experiments). (G) Il17a−/− macrophage mRNA expression was assessed on day three of culture in the presence of recombinant IL-17A (1ng/ml) and compared to control cells (t-tests, 3 independent experiments). (H) Wt macrophage oxLDL uptake on day 7 after culture with different concentrations of recombinant IL-17A (Dunnetts after One-way-ANOVA, n=12, 3 independent experiments).